The nation of Zimbabwe has rejected a significant US healthcare agreement worth $367m (£272m) spanning five years due to the United States' insistence on confidential information.
This rejection became public following a official document from December was leaked, indicating that President Emmerson Mnangagwa felt the agreement was "unbalanced".
An official spokesman later stated that the United States was seeking genetic material for scientific study and profit but was unwilling to share the resulting advantages from future medical innovations.
"We must now begin the challenging and unfortunate process of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished more than $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for further negotiations to find a agreement suitable to all parties so the nation's critical HIV programme can be sustained.
Broader Context
Zimbabwe's decision follows a comparable case in Kenya, where a high court halted a related deal with the US following legal challenges were filed about the safety of Kenyans' health data.
Since returning to office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump argued its expenditure was "inefficient" and his government was seeking government-to-government agreements to boost openness and accountability.
As per statements, 16 African countries have so far signed these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment via US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to share its biological resources and data indefinitely, with no equivalent promise of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"In essence, our country would provide the basic resources for medical research with no certainty that the resulting innovations would be available to our people should a new disease outbreak arise."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were undermining systems previously established through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to manage potential global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its information, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to create them."
These objections over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome further discussions with our US partners on how future collaboration could be designed in a way that honours the independence and interests of each country."
Medical Community Response
Medical experts said it recognised the official position, but recommended that talks need to persist given that much of the nation's HIV programmes depended on foreign aid.
"If technical issues exist, such as those relating to information security or agreement terms, these can frequently be addressed via detailed discussion and mutually agreed protections," the group added.
The halted deal highlights the complex debate between accepting vital international aid and safeguarding a country's data in an increasingly interconnected world.